Orphan Therapies: Making Best Use of Postmarket Data


Postmarket surveillance of the comparative safety and efficacy of orphan therapeutics is challenging, particularly when multiple therapeutics are licensed for the same orphan indication. To make best use of product-specific registry data collected to fulfill regulatory requirements, we propose the creation of a distributed electronic health data network… (More)
DOI: 10.1007/s11606-014-2882-1


2 Figures and Tables